Journal
DIAGNOSTICS
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics11030565
Keywords
BRCA; ovarian cancer; copy number variation; genetic testing
Categories
Funding
- Angela Serra Association for Cancer Research
Ask authors/readers for more resources
This study compared the prognostic and predictive roles of somatic BRCA (sBRCA) mutations versus germline BRCA (gBRCA) mutations in epithelial ovarian cancer patients, finding no significant advantage of sBRCA mutations over gBRCA mutations. The introduction of CNV analysis increased the detection rate of sBRCA mutations, but sBRCA mutation patients did not show any outcome advantage compared to wild-type patients.
Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive impact with regard to overall survival (OS) and platinum and PARP (poly (ADP-ribose) polymerase) inhibitor sensitivity. Nevertheless, molecular testing in these studies did not include copy number variation (CNV) analyses of BRCA genes. The aim of this study was to explore the prognostic and predictive role of sBRCA mutations as compared to gBRCA mutations in patients who were also tested for CNVs. Among the 158 patients included in the study, 17.09% of patients carried a pathogenic or likely pathogenic gBRCA variant and 15.19% of patients presented pathogenetic or likely pathogenic sBRCA variants and/or CNVs. Overall, 81.6% of the patients included in this study were diagnosed with a serous histotype, and 77.2% were in advanced stages. Among women diagnosed in advanced stages, gBRCA patients showed better progression-free survival and OS as compared to sBRCA and wild-type patients, whereas sBRCA patients did not show any advantage in outcome as compared to wild-type patients. In this study, the introduction of CNV analyses increased the detection rate of sBRCA mutations, and the resulting classification among gBRCA, sBRCA and wild-type patients was able to properly stratify the prognosis of OC patients. Particularly, sBRCA mutation patients failed to show any outcome advantage as compared to wild-type patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available